Abbvie gets EU approval for expanded Venclyxto label in CLL
Investing.com · 2026-05-29
STOCKS · PHARMA
ABBV · AbbVie
Latest news, signals, and AI analysis for AbbVie (ABBV) on Catalayer. Updated continuously as stories are indexed across our news feed.
Recent ABBV News
AbbVie receives FDA approval for BPDCN blood cancer treatment
Investing.com · 2026-05-27
Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress
Insider Monkey · 2026-05-27
Related Tickers
$JNJ · Johnson & Johnson$LLY · Eli Lilly$PFE · Pfizer$MRK · Merck$NVO · Novo Nordisk$GILD · Gilead SciencesFrequently Asked Questions
What sector does ABBV belong to?
ABBV (AbbVie) is classified under the Pharma sector on Catalayer. You can browse all news in this sector at /sector/pharma.
Where can I track real-time ABBV news?
Catalayer aggregates ABBV coverage from Reuters, Bloomberg, CNBC, MarketWatch, Yahoo Finance, Seeking Alpha, Barron’s, WSJ, Motley Fool, Benzinga, TipRanks and 20+ other sources. View the live feed at https://catalayer.com/stocks/ABBV.
How fast are ABBV news alerts on Catalayer?
News is polled every 30–60 seconds. ABBV-related stories appear in your workspace within minutes of publication, and you can create a custom monitor to get instant alerts.
Does Catalayer provide AI analysis for ABBV?
Yes. The Market Intelligence tier adds AI-powered event classification (monetary policy, earnings, guidance, M&A), directional impact (bullish/bearish), magnitude, and affected-sector analysis to every ABBV story.
Is ABBV covered in any Catalayer signal channels?
Signal channels and custom keyword monitors both support ABBV. Free accounts get 1 monitor; Plus ($29/mo) unlocks 5 monitors with boolean rules across tickers, sectors, and topics.
Track ABBV in real time
Set up a monitor to get alerted when new news hits.